- Rheinmetall AG (RHM:CA) Q3 2025 Earnings Call Transcript Seeking Alpha
- Financial report for Q3 2025 – Rheinmetall shows steady growth Rheinmetall
- Rheinmetall (RNMBF) Stays on Track Amid Order Delays GuruFocus
- Rheinmetall on track for FY25 targets as backlog rises 22.9% Army Technology
- Rheinmetall looks to international partners as its sales grow Shephard Media
Category: 3. Business
-
Rheinmetall AG (RHM:CA) Q3 2025 Earnings Call Transcript – Seeking Alpha
-

A crisis at chipmaker Nexperia sent automakers scrambling. Here’s what to know
A battle for control of a little-known chipmaker has threatened global auto production by choking off the semiconductor supply chain, though there are signs the crisis is inching toward a resolution.
The power struggle over Nexperia, a Chinese-owned Dutch semiconductor maker, highlights how technology supply chain vulnerabilities are squeezing auto makers, most notably forcing Honda to halt production at a Mexican factory making its popular HR-V crossover for North American markets. It also exposes how Europe is caught in the middle of the wider geopolitical showdown between Washington and Beijing.
Here’s a look at the dispute:
The turmoil erupted into public view in mid-October, when the Dutch government announced it had invoked a rarely used World War II-era law to take effective control of Nexperia weeks earlier.
The Dutch ministry of economic affairs said it took action because of national security concerns. Officials said they intervened because of “serious governance shortcomings” at Nexperia, asserting control to prevent the loss of crucial tech know-how that could threaten Europe’s economic security.
Nexperia’s Chinese owner Wingtech Technology, a partially state-owned company, is at the heart of the dispute. Amid the boardroom battle, a Dutch court granted the ministry’s request to oust Nexperia’s Chinese CEO Zhang Xuezheng. American officials told the Dutch government he would have to be replaced to avoid trade restrictions, according to a court filing.
Nexperia makes simple semiconductors such as switches and logic chips. The auto industry — one of Nexperia’s biggest markets — uses its chips for numerous functions, such as adaptive LED headlight controllers, electric vehicle battery management systems and anti-lock brakes.
Headquartered in the Dutch city of Nijmegen, Nexperia was spun off from Philips Semiconductors two decades ago. It was eventually purchased by China’s Wingtech Technology in 2018 for $3.6 billion.
Nexperia has wafer fabrication plants in Britain and Germany. It operates an assembly and testing center in China’s southern manufacturing heartland of Guangdong — which accounts for around 70% of its end-product capacity — and similar centers in the Philippines and Malaysia.
The dispute is part of the broader struggle between the U.S. and China over tech supremacy, which has left Europe caught in the middle.
It stems from Washington’s decision late last year to place Wingtech on its “entity list,” which subjects companies to export controls because of national security risks. In late September, the U.S. expanded that list to Wingtech’s subsidiaries, including Nexperia, pressuring allies to follow suit.
After the Dutch government asserted control of Nexperia, Beijing responded soon after, blocking the export of Nexperia chips from its assembly plant in the Chinese city of Dongguan. It blamed the Netherlands for “turmoil and chaos” in the chip supply chain.
There were signs of hope following last month’s high-profile meeting between U.S. President Donald Trump and Chinese leader Xi Jinping, when the White House said Beijing would ease the export ban as part of a U.S.-China trade truce.
Despite Beijing also confirming exports would be allowed to resume, Nexperia’s Chinese unit said headquarters suspended shipments of wafers used to make chips to its Chinese factory, potentially crimping its ability to deliver finished products.
Nexperia’s head office hit back in a statement Wednesday, saying the Chinese unit refused to pay for the wafers and accused it of “ignoring the lawful instructions” from its global management team. The company said it can’t guarantee the quality of any chips delivered from its China plant since Oct. 13.
Modern automobiles rely on so-called discrete chips made by companies like Nexperia, which, unlike more advanced microprocessors, perform a single function. Leaders at big carmakers spelled out their worries in the latest round of earnings calls, saying that finding a replacement for Nexperia at scale in the short term will be difficult.
“While Nexperia makes up only about 5% of the automotive silicon discrete market in term of revenue, its share is much higher in terms of discrete chip volume,” S&P Global Mobility analysts wrote in a recent note.
Nexperia’s parts are widely used across vehicle systems — often dozens to hundreds per vehicle — and carmakers in North America, Japan and South Korea are at risk, they added.
“It’s an industrywide issue. A quick breakthrough is really necessary to avoid fourth quarter production losses for the entire industry,” Ford CEO Jim Farley said.
General Motors CEO Mary Barra warned that production could be hit. The company has “teams working around the clock with our supply chain partners to minimize possible disruptions,” she said.
Nissan CEO Ivan Espinosa told CNBC that the company is setting aside a 25 billion yen ($163 million) provision for supply risks, in part to “absorb” the impact from the Nexperia crisis on production.
Mercedes-Benz is “scurrying around the world to look for alternatives,” CEO Ola Kallenius said. The European Automobile Manufacturers’ Association said members including BMW, Renault, Volkswagen and Volvo have been forced to use their reserve stockpiles of chips and warned of assembly line stoppages if they run out.
The European Union’s trade commissioner, Maros Sefcovic, on Saturday noted “encouraging progress,” writing on X that China’s Commerce Ministry had confirmed “further simplification” of export procedures for Nexperia chips to the EU and global customers.
In Beijing, the Commerce Ministry also said Saturday that it agreed to a Dutch request to send representatives to China for “consultations.”
But it noted that the Netherlands had not taken any concrete actions yet to restore the global semiconductor supply chain since the Dutch government said days earlier it would take “appropriate steps on our part where necessary.”
Economics Affairs Minister Vincent Karremans had said in that statement that “the Netherlands trusts that the supply of chips from China to Europe and the rest of the world will reach Nexperia’s customers over the coming days.”
Honda has received word that Nexperia’s shipments from China have resumed, Executive Vice President Noriya Kaihara told reporters Friday. He said the Japanese automaker expects to resume production during the week of Nov. 21 at its plant in Celaya, Mexico, which can make up to 200,000 vehicles a year.
___
AP Business Writer Yuri Kageyama in Tokyo contributed to this report.
Continue Reading
-
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial
Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo
Enlicitide may help address unmet needs in ASCVD, a key driver of the ongoing cardiovascular (CV) epidemic
RAHWAY, N.J.–(BUSINESS WIRE)–
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistically significant and clinically meaningful reduction in low-density lipoprotein cholesterol (LDL-C) of 55.8% (primary analysis; 95% CI: -60.9, -50.7; p<0.001) and of 59.7% in a post-hoc reanalysis (95% CI: -62.3, -57.1; p<0.001) compared to placebo at week 24. These late-breaking data will be presented for the first time today at the American Heart Association (AHA) Scientific Sessions 2025 (Abstract #4391578) and were selected for the Late-Breaking Science News Briefing.In CORALreef Lipids, adults with or at-risk for atherosclerotic cardiovascular disease (ASCVD) on background lipid-lowering therapies or a documented statin intolerance who received once-daily oral enlicitide had statistically significant and clinically meaningful reductions in LDL-C at week 24 (primary endpoint) and statistically significant and sustained reductions in LDL-C through one year (week 52). Enlicitide demonstrated statistically significant reductions in secondary endpoints including non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB) and lipoprotein(a) (Lp(a)) at week 24. The overall safety profile was comparable to placebo. High adherence with study intervention (97%) and dosing instructions (≥97%) were observed across treatment groups.
“Enlicitide demonstrated impressive LDL-C reductions with placebo-like safety in the CORALreef Lipids study, underscoring the practice-changing potential of an oral PCSK9 inhibitor,” said Dr. Ann Marie Navar, a lead author of the study and Associate Professor of Medicine in the Division of Cardiology at UT Southwestern Medical Center. “Despite the availability of lipid-lowering therapies such as statins and injectable PCSK9 inhibitors, the majority of patients with atherosclerotic cardiovascular disease do not reach their LDL-C goal. Enlicitide has the potential to help close gaps in achievement of lipid goals in patients with and at risk for cardiovascular events and ultimately help address the ongoing CV epidemic.”
“Enlicitide was designed to deliver PCSK9 antibody-like efficacy and specificity in an easy-to-use pill,” said Dr. Dean Y. Li, president, Merck Research Laboratories. “Enlicitide, if approved, adds to physicians’ armamentarium to lower LDL-C. This moment is the result of Merck’s legacy and commitment to researching ways to help improve ASCVD outcomes for millions worldwide and our strength in medicinal chemistry using our novel macrocyclic peptide platform. Cardiovascular disease is the leading cause of death globally, and we look forward to bringing a potential new option to help address the CV epidemic.”
At one year, enlicitide showed a sustained statistically significant reduction in LDL-C of 47.6% (primary analysis; 95% CI: -52.7, -42.5; p<0.001) and of 52.4% (post-hoc reanalysis; 95% CI: -55.1, -49.7; p<0.001) compared to placebo. At week 24, enlicitide demonstrated reductions in non-HDL-C of 53.4% (95% CI: -55.5, -51.2; p<0.001), ApoB of 50.3% (95% CI: -52.1, -48.5; p<0.001) and Lp(a) of 28.2% (95% CI: -30.3, -26.0; p<0.001) compared to placebo. The study also showed that 67.5% of patients treated with enlicitide achieved the rigorous prespecified goal of at least 50% reduction in LDL-C along with an LDL-C <55 mg/dL (1.42 mmol/L) compared to 1.2% in the placebo arm at week 24.
Enlicitide had a safety profile similar to placebo. There were no apparent differences between the enlicitide and placebo groups in the incidence of any adverse events (AEs), serious AEs or deaths. Discontinuations due to AEs were low and similar between enlicitide (3.1%) and placebo (4.1%).
Merck plans to share data from this trial, along with data from CORALreef HeFH and CORALreef AddOn with regulatory authorities worldwide.
About CORALreef Lipids
CORALreef Lipids (NCT05952856) is a Phase 3 randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety and tolerability of enlicitide decanoate in adults with hypercholesterolemia and a history of a major atherosclerotic cardiovascular disease (ASCVD) event or increased risk for a first event. Participants were required to be treated with stable lipid-lowering therapies including at least a moderate or high intensity statin (or have documented statin intolerance). The study enrolled 2,912 participants who were randomized 2:1 to receive either 20mg of once-daily oral enlicitide (n=1,942) or placebo (n=970). The primary endpoints were mean percent change in LDL-C from baseline at week 24 versus placebo, number of participants with one or more AEs, and number of participants who discontinued study drug due to an AE. Multiplicity-controlled secondary efficacy endpoints included: mean percent change from baseline in LDL-C at week 52, mean percent change from baseline in other key atherogenic lipids at week 24 (non-HDL-C, ApoB and Lp(a)).
A post-hoc reanalysis was conducted to revise missing data handling rules that resulted in 5 biologically impossible baseline values being included in the primary analysis. The intent of the reanalysis was to provide a more clinically accurate estimate of the treatment effect.
CORALreef Lipids is the largest completed Phase 3 study evaluating enlicitide in a broad range of participants with elevated LDL-C.
About enlicitide and PCSK9
Enlicitide has the potential to be the first FDA approved oral PCSK9 inhibitor. It is designed to lower LDL-C via the same biological mechanism as currently approved monoclonal antibody, injectable PCSK9 inhibitors but in a daily pill form. Enlicitide is a novel small molecule macrocyclic peptide candidate that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors.
PCSK9 plays a key role in cholesterol homeostasis by regulating levels of the LDL receptor, which is responsible for the uptake of cholesterol into cells. Inhibition of PCSK9 is designed to prevent the interaction of PCSK9 with LDL receptors. This results in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
About CORALreef Clinical Trial Program
The efficacy and safety profile of enlicitide is being evaluated through the comprehensive CORALreef Clinical Trial program evaluating over 19,000 participants who have hypercholesterolemia. As previously announced, enlicitide demonstrated statistically significant and clinically meaningful reductions in LDL-C in three pivotal Phase 3 studies: CORALreef Lipids (NCT05952856), CORALreef HeFH (NCT05952869) and CORALreef AddOn (NCT06450366). Enlicitide is continuing to be evaluated in the large cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), which has completed enrollment with over 14,500 participants. Additional CORALreef clinical trials include CORALreef Extension (NCT06492291), CORALreef Pediatric (NCT07058077) and CORALreef Combination (NCT07216482).
About hypercholesterolemia
Hypercholesterolemia, a type of hyperlipidemia, is a disorder in which there are elevated LDL-C levels in the blood. It affects approximately 86 million adults in the U.S. and is a major risk factor for ASCVD. Nearly 70% of people with ASCVD who are treated with lipid-lowering therapies do not reach target LDL cholesterol levels. High LDL-C, if left untreated, can lead to ASCVD events such as heart attacks and strokes.
About the CV epidemic and atherosclerotic cardiovascular disease
The silent CV epidemic is the leading cause of deaths globally, contributing to the majority of heart attacks and strokes, and deaths related to CV continue to rise. ASCVD accounts for 85% of CV deaths. It is caused by the buildup of plaque within the arteries, leading to narrowed or blocked blood vessels that can result in serious CV events such as heart attacks and strokes as well as coronary artery disease, peripheral artery disease and cerebrovascular disease.
Merck’s focus on cardiovascular disease
Merck has a long history of developing treatments for cardiovascular disease. Nearly 70 years ago, we introduced our first cardiovascular therapy—and our scientific efforts to understand and treat cardiovascular-related disorders have continued. Cardiovascular disease continues to be one of the most serious health challenges of the 21st century and is the leading cause of death worldwide. Approximately 18 million people across the globe die from cardiovascular disease every year; in the United States, one person dies every 36 seconds from cardiovascular disease.
Advancements in the treatment of cardiovascular disease can make a critical difference for patients and health systems around the world. At Merck, we strive for scientific excellence and innovation in all stages of research, from discovery through approval and life cycle management. We work with experts throughout the cardiovascular and pulmonary community to advance research that can help improve the lives of patients globally.
Information for other currently enrolling cardiovascular studies can be found by visiting: https://www.merckclinicaltrials.com/cardiovascular.
About Merck
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA
This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2024 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Source: Merck & Co., Inc., Rahway, NJ, USA
Continue Reading
-
Fish Oil Shows Cardiovascular Benefits in Dialysis Patients – Medscape
- Fish Oil Shows Cardiovascular Benefits in Dialysis Patients Medscape
- Fish oil supplementation may reduce CVD risks for people on dialysis Healio
- Fish Oil Cuts Risk of Serious Heart Events in Dialysis Patients MedPage Today
- PISCES: Fish Oil Slashes Cardiovascular Event Risk of Maintenance Dialysis HCPLive
Continue Reading
-

ABC chair warns ‘extremely autocratic’ views of some AI investors could lead to ‘dangerous and sinister’ outcomes | Australian Broadcasting Corporation
The chair of the ABC has warned that AI could become “dangerous and sinister” considering some who finance it hold views that are “extremely autocratic”.
Kim Williams, who has been chair of the national broadcaster since March 2024, is a prolific user of various AI applications, including ChatGPT, Gemini and Perplexity, saying it is important for people to understand the technology.
“I make myself use it and try to understand it … I don’t pretend to be an expert, but I’m certainly actively, passionately interested because it’s the next major technology that is going to change our world,” he told Guardian Australia.
Sign up: AU Breaking News email
“As with all technology, this is an immensely useful tool. But it’s a tool and we should not treat it as so many others … have: in a rather undisciplined, romantic way.”
Williams warned that technology can encompass the values of those who create or control it, and said he was concerned what this might mean for AI.
“There are many value constructs that are reflected in AI that can be seen in some ways as being potentially dangerous and sinister,” he said.
“Many of the participants in the financing – and even in the origination and leadership of some of the AI [companies] – have unusually severe views of human organisation and politics, and in some instances … have views that are extremely autocratic, and believe in an anointed few being in charge of the many.”
Williams said that as a believer in democracy and the contest of ideas, it’s “clearly immensely socially dangerous” for people to limit and censor the views of those they disagree with.
“We should not underestimate the potency and power of these technologies – and we are seeing living examples of the technologies in the hands of some governments, where we have real life demonstrations of just how dangerous this can be.”
Asked whether, he thought media organisations – including News Corp and the Guardian – should be signing deals with AI companies, Williams said everyone needed to carry the responsibility of using these technologies with a sense of the public and national interest.
“I speak about it openly with colleagues because I think these things are immensely important.”
Kim Williams says: ‘I think the impact on journalism will probably be a lot more benign. Well, actually, a lot more positive than people think …’ Photograph: Mike Bowers/The Guardian AI companies failed to insert a text and mining data exemption into Australian copyright law, which would have allowed them to train AI on creative works without paying for it. Last month, the Albanese government ruled out introducing such an exemption.
Williams, who chaired the Copyright Agency for six years said people have a right to derive income from their creative work.
“Anything that is going to compromise that is not cool, and it’s not acceptable, and that is, as far as I know, illegal,” he said.
“And it should get the full … defence and prosecution by government. You’ve got to pay people who have invested their lifetimes in creating works.”
Williams said he saw AI as potentially devastating for entry-level jobs in industries such as accounting or law, but he believed the effect on journalism jobs would not be as damaging.
“I think the impact on journalism will probably be a lot more benign. Well, actually, a lot more positive than people think because journalists are smart, perspicacious people, and they’ll figure out ways that AI will actually make them better and stronger and will improve journalism,” he said.
“But boy, in so many other areas, I just think it can be an employment destroyer.”
Continue Reading
-

A crisis at chipmaker Nexperia sent automakers scrambling. Here’s what to know
A battle for control of a little-known chipmaker has threatened global auto production by choking off the semiconductor supply chain, though there are signs the crisis is inching toward a resolution.
The power struggle over Nexperia, a Chinese-owned Dutch semiconductor maker, highlights how technology supply chain vulnerabilities are squeezing auto makers, most notably forcing Honda to halt production at a Mexican factory making its popular HR-V crossover for North American markets. It also exposes how Europe is caught in the middle of the wider geopolitical showdown between Washington and Beijing.
Here’s a look at the dispute:
A surprise move
The turmoil erupted into public view in mid-October, when the Dutch government announced it had invoked a rarely used World War II-era law to take effective control of Nexperia weeks earlier.
The Dutch ministry of economic affairs said it took action because of national security concerns. Officials said they intervened because of “serious governance shortcomings” at Nexperia, asserting control to prevent the loss of crucial tech know-how that could threaten Europe’s economic security.
Nexperia’s Chinese owner Wingtech Technology, a partially state-owned company, is at the heart of the dispute. Amid the boardroom battle, a Dutch court granted the ministry’s request to oust Nexperia’s Chinese CEO Zhang Xuezheng. American officials told the Dutch government he would have to be replaced to avoid trade restrictions, according to a court filing.
What is Nexperia?
Nexperia makes simple semiconductors such as switches and logic chips. The auto industry — one of Nexperia’s biggest markets — uses its chips for numerous functions, such as adaptive LED headlight controllers, electric vehicle battery management systems and anti-lock brakes.
Headquartered in the Dutch city of Nijmegen, Nexperia was spun off from Philips Semiconductors two decades ago. It was eventually purchased by China’s Wingtech Technology in 2018 for $3.6 billion.
Nexperia has wafer fabrication plants in Britain and Germany. It operates an assembly and testing center in China’s southern manufacturing heartland of Guangdong — which accounts for around 70% of its end-product capacity — and similar centers in the Philippines and Malaysia.
Geopolitics
The dispute is part of the broader struggle between the U.S. and China over tech supremacy, which has left Europe caught in the middle.
It stems from Washington’s decision late last year to place Wingtech on its “entity list,” which subjects companies to export controls because of national security risks. In late September, the U.S. expanded that list to Wingtech’s subsidiaries, including Nexperia, pressuring allies to follow suit.
Continue Reading
-
Nvidia CEO wants TSMC to boost chip supplies amid strong AI demand – Seeking Alpha
- Nvidia CEO wants TSMC to boost chip supplies amid strong AI demand Seeking Alpha
- Nvidia CEO Asks TSMC for More Wafers to Meet Strong AI Demand Bloomberg.com
- The obstacles to Jensen Huang’s AI doctrine Punchbowl News
- TSMC ramps 3 nm production in Taiwan to 160K wafers/month for Nvidia CryptoRank
- Nvidia CEO deepens ties with TSMC with third visit in three months Nikkei Asia
Continue Reading
-

WBCSD Launches Emissions Reduction Accelerator (ERA) and value chain pilots at COP30 to drive business action
- WBCSD launches the Emissions Reduction Accelerator (ERA), a new platform to mobilize business-led, value chain decarbonization at scale.
- ERA pilots will target high-impact interventions for green fertilizers and net zero built assets.
- The business case: ERA’s value chain approach to decarbonization can lower costs, boost resilience, unlock new markets, and strengthen stakeholder trust.
- A Sao Paolo roundtable convened senior executives to endorse ERA, commit to pilot engagement, and shape collective action.
- WBCSD calls on members and forward-looking businesses to engage and help close the emissions gap by 2030.
Sao Paolo, 8 November 2025: The World Business Council for Sustainable Development (WBCSD) has launched its Emissions Reduction Accelerator (ERA), an accelerator designed to mobilize collective business action and unlock value chain decarbonization at scale. ERA was formally introduced as part of the build up to COP30, with the announcement of two flagship value chain pilots focused on scaling emissions reduction in agriculture and the built environment.
A strong business case for value chain decarbonization
ERA is not just a climate imperative – it is a business opportunity. According to a report co-authored by WBCSD and EY, WBCSD members and their value chains account for as much as 15.05 Gt CO₂e (89% of which are Scope 3) – approximately a quarter of annual global greenhouse gas emissions. By focusing on value chain (Scope 3) emissions, companies can address their largest climate impact, while also unlocking tangible business benefits: lower operational costs, enhanced supply chain resilience, improved stakeholder trust, access to new markets, and a lower cost of capital.
Decarbonizing value chains is increasingly demanded by regulators, investors, and customers, and companies that lead will be best positioned for growth and competitiveness.
Two value chain pilots:
Lowering emissions from fertilizer production and use, and net-zero commercial real estate assets
ERA’s initial pilots will target two of the highest-impact value chains: agriculture and the built environment.
The first pilot will focus on lowering emissions from fertilizers, a major source of GHGs in the agri-food value chain. By mapping and engaging all relevant actors – from input providers to farmers to food brands – the pilot will test and scale solutions such as green fertilizers and improved use efficiency, with the potential for global spillover.
The second pilot will address the supply and demand for net zero asset buildings. With the built environment responsible for a significant share of global emissions, this pilot will bring together owners, occupiers, solution providers, and financiers to overcome barriers to retrofitting and decarbonizing real estate assets, including manufacturing facilities, logistics hubs, offices, and data centers.
Sao Paolo high level ERA Roundtable:
A launch moment for collective action
In the lead-up to COP30, WBCSD convened a roundtable in Sao Paolo, bringing together senior business executives from member companies, partners, and invited guests. The session showcased ERA as WBCSD’s platform to accelerate value-chain decarbonization and unlock business value. Key insights from the WBCSD–EY analysis and value-chain mapping by McKinsey were presented, demonstrating clear implementation pathways for the pilots.
Key outcomes:
- Broad endorsement: Participants expressed strong support for ERA’s collaborative approach, recognizing the need for collective action to address scope 3 emissions and unlock business value.
- Pilot engagement: Several companies and partners committed to engaging in the 2026 pilots, contributing expertise and resources to shape the design and implementation of interventions.
- Enabling Conditions: The discussion highlighted the critical role of data, standards, finance, policy, and technology – including AI – in enabling and accelerating emissions reduction across complex value chains.
- Next Steps: WBCSD invited all interested stakeholders to participate in the pilot design phase and contribute to shaping ERA.
A call to action
The next five years must be the years of decisive action to reduce greenhouse gas emissions and avoid the most catastrophic impacts of climate change. This is why accelerating emissions reduction has become a priority focus for WBCSD. We are entering a transformative era shaped by the rapid development of artificial intelligence. These two forces – decarbonization and digitalization – are converging. Acted on consciously and collectively, they can reshape competitiveness, innovation, and impact. Done well, decarbonizing business value chains lowers costs, enhances resilience, mitigates risks, and unlocks new opportunities for growth and investment for all. Climate leadership today must go beyond commitments – no company can reach net zero alone. Collective mobilization across value chains is essential.
– Peter Bakker, President and CEO, WBCSD
ERA is a platform built by business, for business. By engaging with ERA, companies can not only accelerate their own decarbonization journeys but also strengthen their competitiveness, resilience, and long-term value. I invite all WBCSD members and forward-looking businesses everywhere: join us, help design and deliver the ERA pilots, and be part of the business-led transformation that will define the next decade. Together, we can turn ambition into action and deliver real impact for climate and for business.
– Dominic Waughray, Executive Vice President, WBCSD
WBCSD calls on all companies, partners, and stakeholders to join the Emissions Reduction Accelerator and help deliver the business-led solutions needed to close the emissions gap by 2030.
Continue Reading
-

Fear Is Coming Back to the Junk Bond Market: Credit Weekly
Junk bond investors are getting more skittish about risk.
An index of CCC rated bonds in the US has dropped nearly 0.8% over the month ended Thursday, underperforming the broader high-yield market as investors increasingly avoid the riskiest debt. Distressed US dollar loans jumped to $71.8 billion at the end of October — the highest since President Donald Trump outlined his tariff policy in April.
Continue Reading
-
How a ‘one and done’ gene-editing treatment could lower cholesterol – The Washington Post
- How a ‘one and done’ gene-editing treatment could lower cholesterol The Washington Post
- CRISPR Therapeutics (Nasdaq: CRSP) announces 73% ANGPTL3 drop in Phase 1 CTX310 trial Stock Titan
- CRISPR gene therapy slashes ‘bad’ cholesterol, triglycerides by half in small study MarketScreener
- Scientists have edited a gene that may reduce high cholesterol permanently CNN
- First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides www.heart.org
Continue Reading